Summary by Futu AI
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the registration of common stock shares that may be sold by a selling stockholder, Armistice Capital, LLC. The shares in question are issuable upon the exercise of previously issued warrants, including the July 2022 Common Warrants, December 2022 Common Warrants, April 2023 Common Warrants, and December 2023 Common Warrants. The selling stockholder may sell the shares through various methods such as block trades, private transactions, or on the open market. The filing also includes details on indemnification agreements, recent unregistered sales of securities, and the potential impact of the shares' sale on the company's control. The registration allows the selling stockholder to publicly sell their shares, but does not necessarily indicate that they will do so. The company will not receive any proceeds from the sale of shares by the selling stockholder.